| Literature DB >> 29657085 |
Kevin R W Ngoei1, Christopher G Langendorf2, Naomi X Y Ling3, Ashfaqul Hoque3, Swapna Varghese4, Michelle A Camerino5, Scott R Walker5, Ylva E Bozikis5, Toby A Dite3, Ashley J Ovens6, William J Smiles3, Roxane Jacobs7, He Huang8, Michael W Parker9, John W Scott10, Mark H Rider7, Richard C Foitzik11, Bruce E Kemp10, Jonathan B Baell12, Jonathan S Oakhill13.
Abstract
The AMP-activated protein kinase (AMPK) αβγ heterotrimer regulates cellular energy homeostasis with tissue-specific isoform distribution. Small-molecule activation of skeletal muscle α2β2 AMPK complexes may prove a valuable treatment strategy for type 2 diabetes and insulin resistance. Herein, we report the small-molecule SC4 is a potent, direct AMPK activator that preferentially activates α2 complexes and stimulates skeletal muscle glucose uptake. In parallel with the term secretagog, we propose "importagog" to define a substance that induces or augments cellular uptake of another substance. Three-dimensional structures of the glucose importagog SC4 bound to activated α2β2γ1 and α2β1γ1 complexes reveal binding determinants, in particular a key interaction between the SC4 imidazopyridine 4'-nitrogen and β2-Asp111, which provide a design paradigm for β2-AMPK therapeutics. The α2β2γ1/SC4 structure reveals an interaction between a β2 N-terminal α helix and the α2 autoinhibitory domain. Our results provide a structure-function guide to accelerate development of potent, but importantly tissue-specific, β2-AMPK therapeutics.Entities:
Keywords: AMP-activated protein kinase; X-ray crystallography; diabetes; drug development; glucose disposal; importagog; metabolism; secretagog
Mesh:
Substances:
Year: 2018 PMID: 29657085 DOI: 10.1016/j.chembiol.2018.03.008
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116